Hematology

Results showed treatment with iptacopan through 48 weeks caused hemoglobin-level increases, blood transfusion avoidance, and reductions in patient-reported fatigue.

Although more than half of female patients with sickle cell disease reported sickle cell pain associated with their menstrual cycles, only 12.5% had used ≥1 hormonal therapies within the past 3 months.

Study results presented at the 2023 American Society of Hematology Annual Meeting and Exposition found equal immune tolerance induction success rates regardless of race/ethnicity.

The revised algorithm demonstrates 97% sensitivity in identifying pregnant patients with inherited bleeding disorders.

Extension analysis from a phase 1 trial show the investigative oral mitapivat was not associated with any discontinuations nor deaths over 2 years.

New case-control data from ASH 2023 show a particularly increased link between sickle cell trait and monocytic and myeloid leukemia progression.

These findings presented at ASH show promise for future studies on GBT02601 as a potential alternative to voxelotor for sickle cell disease.

This new data on a European sickle cell disease cohort expands upon existing knowledge of the effects of HU on fertility, with the findings showing the benefits of cryopreservation.

Results of the phase 2 RISE UP trial offer additional perspective into the benefit-risk profile of mitapivat in patients with sickle cell disease.

Bezuclastinib, a targeted oral therapy, shows promise in reducing disease burden and improving symptoms by 50% or more in nonadvanced systemic mastocytosis patients, as revealed in the phase 2 SUMMIT trial data presented at ASH 2023.

A single-center cohort analysis showed the biosimilar provided similar PBSC mobilization to originator filgrastim.

A study followed a neonatal cohort with sickle cell disease for up to 20 years. The study demonstrated how hydroxyurea lowers the risk of high mortality.

60.2% of infant living-related liver transplant recipients developed AKI within 7 days of surgery and experienced more frequent serious complications, longer hospital stays, and a greater duration of postoperative mechanical ventilation compared to those who did not develop AKI.

The FDA announced it has approved Adzynma as prophylactic or on-demand enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura.

Investigators studied factors that could be associated with anemia in children < 5 years old, such as gender, age in years, type of birth (single or multiple), birth order, preceding birth interval in months (<18 months, 18+ months, or 1st born), and fever or no fever in the past 2 weeks (with malaria and without). Other factors related to mother or caregiver characteristics and household characteristics.

Decreased blood serum cholesterol levels were associated with an increased risk of plasma cell neoplasm, although there was no causal association with multiple myeloma.

A new study reveals that H. pylori is associated with low serum ferritin. In the study, H. pylori infection was associated with a 28.8% decreased serum ferritin, meaning the infection is linked to less iron stored in the body.

In a new study, upper endoscopy identified the cause of iron deficiency anemia in more than 70% of children.

A large pediatric study suggests the diagnostic marker is both reliable and practical with high sensitivity and acceptable specificity for identifying iron deficiency and iron deficiency anemia.

Results from a series of focus group discussions revealed donors, collection staff, and physicians supported iron supplementation if donors were given freedom of choice and necessary information about iron deficiency and supplementation.

Presented at United European Gastroenterology Week 2023, results of the retrospective study showed ferric maltol was safe for us in pregnant patients with IBD and iron deficiency anemia.

The SGLT2 inhibitor demonstrated possible erythropoietic effects in type 2 diabetes patients.

Eltrombopag (Promacta) was granted Priority Review designation, indicating a 6-month timeline for review.

Anemia could increase the prevalence of restless legs syndrome in patients with lupus.